CoChat
Sign Up
Cited by 1,789

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017

Ostrom, Quinn T, Patil, Nirav, Cioffi, Gino, Waite, Kristin, Kruchko, Carol, Barnholtz-Sloan, Jill S·2020·Neuro-Oncology
DOI 10.1093/neuonc/noaa200
Open this paper in CoChat — free account

Abstract

The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control (CDC) and National Cancer Institute (NCI), is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors (malignant and non-malignant) and supersedes all previous CBTRUS reports in terms of completeness and accuracy. All rates (incidence and mortality) are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 23.79 (Malignant AAAIR=7.08, non-Malignant AAAIR=16.71). This rate was higher in females compared to males (26.31 versus 21.09), Blacks compared to Whites (23.88 versus 23.83), and non-Hispanics compared to Hispanics (24.23 versus 21.48). The most commonly occurring malignant brain and other CNS tumor was glioblastoma (14.5% of all tumors), and the most common non-malignant tumor was meningioma (38.3% of all tumors). Glioblastoma was more common in males, and meningioma was more common in females. In children and adolescents (age 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.14. An estimated 83,830 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US in 2020 (24,970 malignant and 58,860 non-malignant). There were 81,246 deaths attributed to malignant brain and other CNS tumors between 2013 and 2017. This represents an average annual mortality rate of 4.42. The 5-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 23.5% and for a non-malignant brain and other CNS tumor was 82.4%.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/noaa200

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 89

  1. Kruchko, 2018, The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone, Neuro. Oncol., 20, 295, 10.1093/neuonc/noy006 · DOI
  2. Louis, 2007, WHO Classification of Tumours of the Central Nervous System
  3. Ostrom, 2014, CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011, Neuro. Oncol., 16, iv1, 10.1093/neuonc/nou223 · DOI
  4. Walker, 2019, Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013, Neuro. Oncol., 21, 360, 10.1093/neuonc/noy195 · DOI
  5. Wohrer, 2009, The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry, Journal of neuro-oncology, 95, 401, 10.1007/s11060-009-9938-9 · DOI
  6. Asklund, 2015, Brain tumors in Sweden: data from a population-based registry 1999-2012, Acta oncologica, 54, 377, 10.3109/0284186X.2014.975369 · DOI
  7. Centers for Disease Control and Prevention National Center for Health Statistics, 2020, National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database: U.S. Cancer Statistics Incidence Analytic Database – 2001-2017
  8. Fritz, 2000, International Classification of Diseases for Oncology
  9. Bray, 2017, Data Comparability and Quality, Cancer Incidence in Five Continents, Vol. XI (electronic version)
  10. McCarthy, 2002, Consensus Conference on Brain Tumor Definition for registration. November 10, 2000, 134
  11. Steliarova-Foucher, 2005, International Classification of Childhood Cancer, third edition, Cancer., 103, 1457, 10.1002/cncr.20910 · DOI
  12. Swerdlow, 2007, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
  13. Kleihues, 2000, Tumours of the nervous system: World Health Organization classification of tumours
  14. Louis, 2016, WHO Classification of Tumours of the Central Nervous System
  15. Ostrom, 2016, Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying), J Neurooncol, 130, 31, 10.1007/s11060-016-2217-7 · DOI
  16. Lym, 2015, Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011, J. Neurooncol., 10.1007/s11060-015-1775-4 · DOI
  17. Hočevar, 2016, Computation of Graphlet Orbits for Nodes and Edges in Sparse Graphs, 2016, 71, 24
  18. Pebesma, 2018, Simple Features for R: Standardized Support for Spatial Vector Data, The R Journal, 10, 439, 10.32614/RJ-2018-009 · DOI
  19. Tiwari, 2006, Efficient interval estimation for age-adjusted cancer rates, 547
  20. Fay, 2006, Estimating average annual percent change for disease rates without assuming constant change, Biometrics., 62, 847, 10.1111/j.1541-0420.2006.00528.x · DOI
  21. Kim, 2000, Permutation tests for joinpoint regression with applications to cancer rates, Stat. Med., 19, 335, 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z · DOI
  22. Zhu, 2012, Predicting US- and state-level cancer counts for the current calendar year: Part II: evaluation of spatiotemporal projection methods for incidence, Cancer., 118, 1100, 10.1002/cncr.27405 · DOI
  23. Chu, 1994, A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer, J. Clin. Epidemiol., 47, 1451, 10.1016/0895-4356(94)90089-2 · DOI
  24. Surveillance Epidemiology and End Results (SEER) Program, 2020, SEER*Stat Database: Incidence - SEER Research Data, 9 Registries, Nov 2019 Sub (1975-2017) - Linked To County Attributes - Time Dependent (1990-2017) Income/Rurality, 1969-2017 Counties
  25. Louis, 2016, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol., 131, 803, 10.1007/s00401-016-1545-1 · DOI
  26. Ferlay, Histological groups.
  27. Ostrom, 2020, Pilocytic astrocytomas: where do they belong in cancer reporting?, Neuro. Oncol., 22, 298
  28. Edwards, 2014, Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer, Cancer, 120, 1290, 10.1002/cncr.28509 · DOI
  29. Zullig, 2012, Cancer incidence among patients of the U.S. Veterans Affairs Health Care System, Mil. Med., 177, 693, 10.7205/MILMED-D-11-00434 · DOI
  30. Clegg, 2002, Impact of reporting delay and reporting error on cancer incidence rates and trends, 1537
  31. Midthune, 2005, Modeling Reporting Delays and Reporting Corrections in Cancer Registry Data, Journal of the American Statistical Association, 100, 61, 10.1198/016214504000001899 · DOI
  32. Li, 2016, Are Benign and Borderline Brain Tumors Underreported?, J Registry Manag., 43, 187
  33. Anderson, 1998, Report of the Second Workshop on Age Adjustment, Vital Health Stat. 4., I-vi, 1
  34. Anderson, 1998, Age standardization of death rates: implementation of the year 2000 standard, Natl. Vital Stat. Rep., 47, 1
  35. Johnson, 2007, The 2007 Multiple Primary and Histology Coding Rules
  36. Ostrom, 2018, Females have the survival advantage in glioblastoma, Neuro. Oncol., 20, 576, 10.1093/neuonc/noy002 · DOI
  37. Ostrom, 2018, Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014, JAMA Oncol, 4, 1254, 10.1001/jamaoncol.2018.1789 · DOI
  38. Siegel, 2019, Cancer statistics, 2019, CA Cancer J Clin., 69, 7, 10.3322/caac.21551 · DOI · Paper page
  39. Zhang, 2016, Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010, Neuro. Oncol., 10.1093/neuonc/now252 · DOI
  40. Gittleman, 2018, Survivorship in Adults with Malignant Brain and other Central Nervous System Tumor from 2000-2014, Neuro. Oncol., 10.1093/neuonc/noy090 · DOI
  41. 2012, DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.7 Surveillance Research Program, Statistical Methodology and Applications
  42. Fay, 2003, Age-conditional probabilities of developing cancer, Stat. Med., 22, 1837, 10.1002/sim.1428 · DOI
  43. Fay, 2004, Estimating age conditional probability of developing disease from surveillance data, Population health metrics., 2, 6, 10.1186/1478-7954-2-6 · DOI
  44. Surveillance Epidemiology and End Results (SEER) Program, DevCan database: “SEER 18 Incidence and Mortality, 2000-2016, with Kaposi Sarcoma and Mesothelioma”
  45. Braganza, 2012, Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review, Neuro. Oncol., 14, 1316, 10.1093/neuonc/nos208 · DOI
  46. Amirian, 2016, Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study, Cancer Epidemiol Biomarkers Prev., 25, 282, 10.1158/1055-9965.EPI-15-0847 · DOI
  47. Malmer, 2003, Familial brain tumours—genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients, Int. J. Cancer., 106, 260, 10.1002/ijc.11213 · DOI
  48. Wrensch, 1997, Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls, Am. J. Epidemiol., 145, 581, 10.1093/oxfordjournals.aje.a009154 · DOI
  49. Malmer, 1999, Familial aggregation of astrocytoma in northern Sweden: An epidemiological cohort study, Int. J. Cancer., 81, 366, 10.1002/(SICI)1097-0215(19990505)81:3<366::AID-IJC9>3.0.CO;2-0 · DOI
  50. Hill, 2003, Cancer in first-degree relatives and risk of glioma in adults, Cancer Epidemiol Biomarkers Prev., 12, 1443
  51. Scheurer, 2007, Aggregation of cancer in first-degree relatives of patients with glioma, Cancer Epidemiol Biomarkers Prev., 16, 2491, 10.1158/1055-9965.EPI-07-0576 · DOI
  52. Claus, 2011, Family and personal medical history and risk of meningioma, J Neurosurg., 115, 1072, 10.3171/2011.6.JNS11129 · DOI
  53. Ostrom, 2014, The epidemiology of glioma in adults: a “state of the science” review, Neuro. Oncol., 16, 896, 10.1093/neuonc/nou087 · DOI
  54. Johnson, 2014, Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review, Cancer Epidemiol Biomarkers Prev., 23, 2716, 10.1158/1055-9965.EPI-14-0207 · DOI
  55. Wiemels, 2010, Epidemiology and etiology of meningioma, J. Neurooncol., 99, 307, 10.1007/s11060-010-0386-3 · DOI
  56. Scheie, 2019, Biomarkers in tumors of the central nervous system - a review, APMIS., 127, 265, 10.1111/apm.12916 · DOI
  57. Velazquez Vega, 2018, Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics, Adv. Anat. Pathol., 25, 143, 10.1097/PAP.0000000000000186 · DOI
  58. Guerreiro Stucklin, 2018, Review of molecular classification and treatment implications of pediatric brain tumors, Curr. Opin. Pediatr., 30, 3, 10.1097/MOP.0000000000000562 · DOI
  59. Reifenberger, 2017, Advances in the molecular genetics of gliomas - implications for classification and therapy, Nat. Rev. Clin. Oncol., 14, 434, 10.1038/nrclinonc.2016.204 · DOI · Paper page
  60. Cairncross, 1998, Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas, J. Natl. Cancer. Inst., 90, 1473, 10.1093/jnci/90.19.1473 · DOI
  61. Cairncross, 2013, Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402, J. Clin. Oncol., 31, 337, 10.1200/JCO.2012.43.2674 · DOI
  62. Vogelbaum, 2015, Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131, J. Neurooncol., 124, 413, 10.1007/s11060-015-1845-7 · DOI
  63. van den Bent, 2013, Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951, J. Clin. Oncol., 31, 344, 10.1200/JCO.2012.43.2229 · DOI
  64. Eckel-Passow, 2015, Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors, N. Engl. J. Med., 372, 2499, 10.1056/NEJMoa1407279 · DOI
  65. Qi, 2014, Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms, Oncol. Lett., 7, 1895, 10.3892/ol.2014.2013 · DOI
  66. Paldor, 2016, Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors, J Clin Neurosci., 34, 128, 10.1016/j.jocn.2016.05.017 · DOI
  67. Ceccarelli, 2016, Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma, Cell., 164, 550, 10.1016/j.cell.2015.12.028 · DOI
  68. Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N. Engl. J. Med., 352, 997, 10.1056/NEJMoa043331 · DOI · Paper page
  69. Hegi, 2008, Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity, J. Clin. Oncol., 26, 4189, 10.1200/JCO.2007.11.5964 · DOI
  70. Stupp, 2007, Chemoradiotherapy in malignant glioma: standard of care and future directions, J. Clin. Oncol., 25, 4127, 10.1200/JCO.2007.11.8554 · DOI
  71. Noushmehr, 2010, Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma, Cancer Cell., 17, 510, 10.1016/j.ccr.2010.03.017 · DOI · Paper page
  72. van den Bent, 2013, MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951, Clin. Cancer Res., 19, 5513, 10.1158/1078-0432.CCR-13-1157 · DOI
  73. Kool, 2012, Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas, Acta Neuropathol., 123, 473, 10.1007/s00401-012-0958-8 · DOI
  74. Northcott, 2012, Molecular subgroups of medulloblastoma, Expert Rev. Neurother., 12, 871, 10.1586/ern.12.66 · DOI
  75. Northcott, 2012, Medulloblastomics: the end of the beginning, Nat. Rev. Cancer., 12, 818, 10.1038/nrc3410 · DOI
  76. Jones, 2014, Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma, Nat. Rev. Cancer., 14, 10.1038/nrc3811 · DOI
  77. Wu, 2014, The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma, Nat. Genet., 46, 444, 10.1038/ng.2938 · DOI
  78. Mackay, 2017, Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma, Cancer Cell, 32, 520, 10.1016/j.ccell.2017.08.017 · DOI · Paper page
  79. Hoffman, 2016, Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics, Acta Neuropathol. Commun., 4, 1, 10.1186/s40478-015-0269-0 · DOI
  80. Grill, 2012, Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma, Pediatr. Blood Cancer., 58, 489, 10.1002/pbc.24060 · DOI
  81. Lapin, 2017, Genomic Insights into Diffuse Intrinsic Pontine Glioma, Front. Oncol., 7, 57, 10.3389/fonc.2017.00057 · DOI
  82. Ostrom, 2016, Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying), J. Neurooncol, 130, 31, 10.1007/s11060-016-2217-7 · DOI
  83. Weir, 2014, Evaluation of North American Association of Central Cancer Registries’ (NAACCR) data for use in population-based cancer survival studies, Journal of the National Cancer Institute Monogr., 2014, 198, 10.1093/jncimonographs/lgu018 · DOI
  84. Wilson, 2014, Coding completeness and quality of relative survival-related variables in the National Program of Cancer Registries Cancer Surveillance System, 1995-2008, J Registry Manag, 41, 65
  85. Kleihues, 1993, The new WHO classification of brain tumours, Brain Pathol., 3, 255, 10.1111/j.1750-3639.1993.tb00752.x · DOI
  86. van den Bent, 2010, Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective, Acta Neuropathol., 120, 297, 10.1007/s00401-010-0725-7 · DOI · Paper page
  87. Aldape, 2000, Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study, Cancer., 88, 2342, 10.1002/(SICI)1097-0142(20000515)88:10<2342::AID-CNCR19>3.0.CO;2-X · DOI
  88. Sahm, 2014, Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma, Acta Neuropathol., 128, 551, 10.1007/s00401-014-1326-7 · DOI
  89. Kruchko, 2019, Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors, Neurooncol Pract., 6, 330

Cited by

Sorted by citations

See all 1,789

Metadata

Authors
Ostrom, Q. T., Patil, N., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S.
Affiliations
Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA
Venue
Neuro-Oncology
Publisher
Oxford University Press (OUP)
Published
2020-10
Volume
22
Issue
Supplement_1
Pages
iv1-iv96
ISSN
  • 1522-8517
  • 1523-5866
DOI
10.1093/neuonc/noaa200
Cited by
1,789
References
6
Language
en
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Funders
  • Centers for Disease Control and Prevention (2016-M-9030)
  • Cancer Prevention and Research Institute of Texas (RP160097T)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. https://app.cochat.ai/papers/10.1093/neuonc/noaa200
The paper
Ostrom, Q. T., Patil, N., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2020). CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaa200